Creating Biomedical Technologies to Improve Health

Search form



Grantee News • May 20, 2015

NIBIB-funded bioengineers at the Massachusetts Institute of Technology demonstrated the role of geometry in the function of biomedical implants. The group implanted capsules carrying insulin-producing cells into a diabetic mouse model demonstrating that increased capsule size significantly reduced the immune response to the capsule allowing it to function five times longer than a more conventional, smaller capsule. Read more at MIT News.

Science Highlights • May 20, 2015
NIBIB-funded researchers have developed a highly sensitive and accurate imaging technique for non-invasive screening of lymph nodes for metastatic cancer. Current practice calls for invasive surgical biopsies to determine whether deadly metastatic cancer cells have invaded the lymph nodes. The new imaging technique – so far tested in mice – offers a rapid and effective tool to noninvasively identify very small numbers of these cells, known as micrometastases, thus detecting cancer’s spread at its earliest stages, which is critical for timely treatment.
Press Releases • May 18, 2015
Researchers have developed a microfluidic chip that can capture rare clusters of circulating tumor cells, which could yield important new insights into how cancer spreads. The work was funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB), part of the National Institutes of Health.
Grantee News • May 18, 2015

NIBIB-funded researchers have designed a nanoparticle-based treatment that inhibits breast cancer metastasis in a mouse model. The nanoparticle carries an siRNA that silences the gene for Beta-3 integrin--a protein that is responsible for the metastasis of breast cancer to other sites in the body. The research team developed the system for difficult-to-treat triple-negative breast cancer and hope to move their experiments from animal models to clinical trials. Read more at ScienceDaily.

Grantee News • May 6, 2015

The Wall Street Journal reports on a novel method for regenerating a meniscus, the pad that serves as a shock absorber between the thigh and shin bones. The technique, developed with funding support from NIBIB, uses a 3D printer to make a scaffold of a person's meniscus using a biodegradable material. The scaffold is then filled with growth factors that coax stem cells to grow a new meniscus inside the joint. The technique was recently successfully tested in sheep. Read more at

NIBIB in the News • May 6, 2015

NIBIB Director Roderic I. Pettigrew, PhD, M.D, appeared before the Senate Health, Education, Labor, and Pensions Committee on April 28th to discuss the future of medical innovations for patients. Read more at Federal Telemedicine News.

Science Highlights • May 5, 2015

Scientists have developed and combined new paper and flexible polymer substrates with special sensing devices for rapid and accurate detection of pathogens such as HIV, as well as other biotargets. These novel technologies offer the type of robust, simple, and inexpensive biosensing systems required to provide point-of-care health care in remote areas, where there is minimal diagnostic infrastructure or equipment and a lack of trained medical technicians.

Grantee News • April 21, 2015

NIBIB-funded scientists joined with nearly 300 international researchers to identify gene variants that determine genetic processes and may underlie neuropsychiatric diseases. The study combined the analysis of genetic data from over 190 institutes with MRI scans from more than 30,000 individuals. Read more at MedicalXpress news.

Science Highlights • April 20, 2015
An NIBIB grantee has developed an ultrafast camera that can acquire two-dimensional images at 100 billion frames per second, a speed capable of revealing light pulses traveling through space. By attaching the camera to a microscope, researchers hope to gain valuable insights into biological phenomena previously too fast to be observed.
Grantee News • April 16, 2015

NIBIB-funded researchers have partnered with a collaborative group to develop a new generation of anti-viral treatments. The group reports the development of a compound that drives HIV to lethal mutagenesis. The strategy takes advantage of HIV's already high mutation rate by forcing it above an intolerable threshold where the virus acquires so many mutations that it breaks down and can no longer replicate. Read more at UChicago News.